Yifan Pharmaceutical Co., Ltd.

002019

CNE000001K65

YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Yifan Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.06 CNY

Average target price

18.33 CNY

Spread / Average Target

+40.35%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
YIFAN PHARMACEUTICAL CO., LTD.	-11.64%	2.19B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.81%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+11.75%	14.09B
CIPLA LIMITED	+12.97%	13.64B
ZYDUS LIFESCIENCES LIMITED	+39.74%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
13.06 ^CNY	+1.01%		+19.49%	-11.64%

Apr. 25	Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps	MT
Apr. 25	Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection	MT

Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps	Apr. 25	MT
Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection	Apr. 25	MT
Three Drugs of Yifan Pharmaceutical's Unit Placed in China's Centralized Procurement	Apr. 25	MT
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 19	CI
Yifan Pharmaceutical Gets EU Nod to Sell Ryzneuta Drug	Mar. 26	MT
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023.	Dec. 19	CI
Yifan Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 31, 2023, has closed with 2,412,900 shares, representing 0.2% for CNY 38 million.	Dec. 18	CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023.	23-10-09	CI
Yifan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	23-08-30	CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Yifan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-08-28	CI
Yifan Pharma CFO Resigns; Successor Named	23-07-10	MT
Yifan Pharma Registers Leukemia Drug in China	23-06-30	MT
Yifan Pharmaceutical Registers Coronary Syndrome Treatment	23-06-21	MT
Yifan Pharmaceutical Unit Registers Cancer Treatment in China	23-05-10	MT
Yifan Pharmaceutical Registers Dopamine Hydrochloride	23-05-09	MT
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Yifan Pharma Gets Nod to Register Another Hypotension Drug	23-03-27	MT
Yifan Pharmaceutical Registers Blood Pressure Control Drug	23-03-23	MT
Yifan Pharma Registers Seizure Drug in China	23-03-13	MT
Yifan Pharmaceutical Gets Registration Certificate for Lacosamide Tablets	23-02-27	MT
Aurobindo Pharma Unit Ties Up with Evive to Commercialize Ryzneuta in US	22-11-23	MT